Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

BACKGROUND: Non-small cell cancer (NSCLC) patients with concomitant epidermal growth factor receptor (EGFR) and TP53 mutations have a poor prognosis with the treatment of tyrosine kinase inhibitors (TKIs), and may benefit from a combination regimen preferentially. The present study aims to compare t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Haiyan, Ren, Peng, Chen, Yongzi, Lan, Lan, Yan, Zhuchen, Yang, Yinli, Wang, Bin, Wang, Cong, Li, Yanwei, Li, Ling, Zhang, Yu, Li, Yanyang, Wang, Zuolin, Pan, Zhanyu, Jiang, Zhansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979422/
https://www.ncbi.nlm.nih.gov/pubmed/36864384
http://dx.doi.org/10.1186/s12885-023-10637-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979422/
https://www.ncbi.nlm.nih.gov/pubmed/36864384
http://dx.doi.org/10.1186/s12885-023-10637-4

Ejemplares similares